Pacific Biosciences of California Inc (PACB) Testing Investors’ Patience Right Now
Currently, there are 300.04M common shares owned by the public and among those 264.16M shares have been available to trade. The company’s stock has a 5-day price change of -4.00% and 5.88% over the past three months. PACB shares are trading -4.00% year to date (YTD), with the 12-month market performance down to -21.31% lower. […]
Uncovering Institutional Buying In Pacific Biosciences of California Inc (NASDAQ: PACB)
Currently, there are 300.04M common shares owned by the public and among those 264.16M shares have been available to trade. The company’s stock has a 5-day price change of 24.03% and 25.98% over the past three months. PACB shares are trading 33.33% year to date (YTD), with the 12-month market performance down to -12.57% lower. […]
Why Should You Put Pacific Biosciences of California Inc (NASDAQ: PACB) On Your Portfolio?
Currently, there are 300.04M common shares owned by the public and among those 264.16M shares have been available to trade. The company’s stock has a 5-day price change of 4.20% and 8.77% over the past three months. PACB shares are trading -8.49% year to date (YTD), with the 12-month market performance down to -32.24% lower. […]
Is Pacific Biosciences of California Inc (NASDAQ: PACB) Back In The Buying Zone?
Currently, there are 300.04M common shares owned by the public and among those 264.16M shares have been available to trade. The company’s stock has a 5-day price change of -13.04% and -9.77% over the past three months. PACB shares are trading -23.57% year to date (YTD), with the 12-month market performance down to -34.43% lower. […]
These Numbers Could Change Investor Views For Pacific Biosciences of California Inc (NASDAQ: PACB)
Currently, there are 300.04M common shares owned by the public and among those 264.16M shares have been available to trade. The company’s stock has a 5-day price change of 15.00% and 11.29% over the past three months. PACB shares are trading -24.59% year to date (YTD), with the 12-month market performance down to -30.30% lower. […]
Pacific Biosciences of California Inc (PACB) Volatility Spurs A Quest For Clarity
Currently, there are 300.04M common shares owned by the public and among those 264.16M shares have been available to trade. The company’s stock has a 5-day price change of 18.29% and -14.29% over the past three months. PACB shares are trading -37.70% year to date (YTD), with the 12-month market performance down to -36.67% lower. […]
Is Pacific Biosciences of California Inc (NASDAQ: PACB) Back In The Buying Zone?
Currently, there are 300.04M common shares owned by the public and among those 264.16M shares have been available to trade. The company’s stock has a 5-day price change of 15.36% and -22.22% over the past three months. PACB shares are trading -42.62% year to date (YTD), with the 12-month market performance down to -45.88% lower. […]
Reassessing The Changing Outlook For Pacific Biosciences of California Inc (PACB)
Currently, there are 300.04M common shares owned by the public and among those 264.16M shares have been available to trade. The company’s stock has a 5-day price change of -10.76% and -41.65% over the past three months. PACB shares are trading -50.26% year to date (YTD), with the 12-month market performance down to -50.80% lower. […]
Pacific Biosciences of California Inc (NASDAQ: PACB): Hunting Genuine Value In Market Debris
Currently, there are 300.04M common shares owned by the public and among those 264.15M shares have been available to trade. The company’s stock has a 5-day price change of -7.59% and -44.05% over the past three months. PACB shares are trading -43.44% year to date (YTD), with the 12-month market performance down to -53.59% lower. […]
Growing Through Challenges? – Pacific Biosciences of California Inc (PACB)
Currently, there are 267.44M common shares owned by the public and among those 253.36M shares have been available to trade. Insiders at the company have transacted a total of 19 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 7 of these insider trades were purchases, […]